Joshua Hexter - 31 Dec 2025 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Role
COO & CBO
Signature
/s/ Joshua Hexter
Issuer symbol
ORMP
Transactions as of
31 Dec 2025
Net transactions value
$0
Form type
4
Filing time
05 Jan 2026, 17:20:45 UTC
Previous filing
11 Feb 2025
Next filing
29 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hexter Joshua COO & CBO 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK /s/ Joshua Hexter 05 Jan 2026 0001573235

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORMP Common Stock Award $0 +97,328 +12% $0.000000 930,495 31 Dec 2025 Direct F1
transaction ORMP Common Stock Award $0 +115,000 +12% $0.000000 1,045,495 31 Dec 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORMP Performance Stock Units Award $0 +19,000 $0.000000 19,000 31 Dec 2025 Common Stock 19,000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.
F2 Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
F3 Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.